[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f6mdXc_GTqlxouuPEFwWFhu3HO5rd9SBUSuDVqFblGBg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":33,"rows":40},"University of Magdeburg",[4],35,false,0,1,1040112,27,[13,16,19,21,24,26,28,30],{"name":14,"count":15},"Stroke",4,{"name":17,"count":18},"Glaucoma",3,{"name":20,"count":18},"Hemianopia",{"name":22,"count":23},"Hepatocellular Carcinoma",2,{"name":25,"count":23},"Prostate Cancer",{"name":27,"count":23},"Optic Nerve Diseases",{"name":29,"count":23},"Optic Nerve Injuries",{"name":31,"count":23},"Optic Neuropathies",[],[34,35,36,37,38,39],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[41,69,87,112,150,168,186,204,229,257,275,293,321,339,357],{"intervention":42,"totalTrials":9,"cells":43},"skinoren",{"EARLY_PHASE1":44,"PHASE1":46,"PHASE2":48,"PHASE3":50,"PHASE4":52,"NA":67},{"trials":45,"activeCount":8},[],{"trials":47,"activeCount":8},[],{"trials":49,"activeCount":8},[],{"trials":51,"activeCount":8},[],{"trials":53,"activeCount":8},[54],{"nctId":55,"briefTitle":56,"status":57,"phases":58,"primaryCompletion":59,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":65},"NCT01387048","Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin","COMPLETED",[38],"2012-08","2012-10","2011-08",60,[64],"Acne Vulgaris",[42,66,42],"differin",{"trials":68,"activeCount":8},[],{"intervention":66,"totalTrials":9,"cells":70},{"EARLY_PHASE1":71,"PHASE1":73,"PHASE2":75,"PHASE3":77,"PHASE4":79,"NA":85},{"trials":72,"activeCount":8},[],{"trials":74,"activeCount":8},[],{"trials":76,"activeCount":8},[],{"trials":78,"activeCount":8},[],{"trials":80,"activeCount":8},[81],{"nctId":55,"briefTitle":56,"status":57,"phases":82,"primaryCompletion":59,"completion":60,"start":61,"enrollment":62,"conditions":83,"interventions":84},[38],[64],[42,66,42],{"trials":86,"activeCount":8},[],{"intervention":88,"totalTrials":9,"cells":89},"irbesartan",{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":94,"PHASE3":96,"PHASE4":98,"NA":110},{"trials":91,"activeCount":8},[],{"trials":93,"activeCount":8},[],{"trials":95,"activeCount":8},[],{"trials":97,"activeCount":8},[],{"trials":99,"activeCount":8},[100],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":62,"conditions":107,"interventions":109},"NCT00613496","Irbesartan and Adhesion Molecules in AF","UNKNOWN",[38],"2010-05","2009-05",[108],"Persistent Atrial Fibrillation",[88],{"trials":111,"activeCount":8},[],{"intervention":113,"totalTrials":23,"cells":114},"Rituximab",{"EARLY_PHASE1":115,"PHASE1":117,"PHASE2":119,"PHASE3":144,"PHASE4":146,"NA":148},{"trials":116,"activeCount":8},[],{"trials":118,"activeCount":8},[],{"trials":120,"activeCount":8},[121,134],{"nctId":122,"briefTitle":123,"status":103,"phases":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":130},"NCT00384553","Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma",[35,36],"2010-06","2004-06",30,[129],"Non-Hodgkin's Lymphoma",[113,131,132,133],"DHAP","TEC","autologous stem cell transplantation",{"nctId":135,"briefTitle":136,"status":103,"phases":137,"completion":138,"start":139,"enrollment":127,"conditions":140,"interventions":142},"NCT00385125","Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL",[36],"2010-08","2004-08",[141],"Lymphoma, High-Grade",[143,113],"Bendamustine",{"trials":145,"activeCount":8},[],{"trials":147,"activeCount":8},[],{"trials":149,"activeCount":8},[],{"intervention":131,"totalTrials":9,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":162,"PHASE4":164,"NA":166},{"trials":153,"activeCount":8},[],{"trials":155,"activeCount":8},[],{"trials":157,"activeCount":8},[158],{"nctId":122,"briefTitle":123,"status":103,"phases":159,"completion":125,"start":126,"enrollment":127,"conditions":160,"interventions":161},[35,36],[129],[113,131,132,133],{"trials":163,"activeCount":8},[],{"trials":165,"activeCount":8},[],{"trials":167,"activeCount":8},[],{"intervention":132,"totalTrials":9,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":180,"PHASE4":182,"NA":184},{"trials":171,"activeCount":8},[],{"trials":173,"activeCount":8},[],{"trials":175,"activeCount":8},[176],{"nctId":122,"briefTitle":123,"status":103,"phases":177,"completion":125,"start":126,"enrollment":127,"conditions":178,"interventions":179},[35,36],[129],[113,131,132,133],{"trials":181,"activeCount":8},[],{"trials":183,"activeCount":8},[],{"trials":185,"activeCount":8},[],{"intervention":133,"totalTrials":9,"cells":187},{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":189,"activeCount":8},[],{"trials":191,"activeCount":8},[],{"trials":193,"activeCount":8},[194],{"nctId":122,"briefTitle":123,"status":103,"phases":195,"completion":125,"start":126,"enrollment":127,"conditions":196,"interventions":197},[35,36],[129],[113,131,132,133],{"trials":199,"activeCount":8},[],{"trials":201,"activeCount":8},[],{"trials":203,"activeCount":8},[],{"intervention":205,"totalTrials":9,"cells":206},"BIBW 2992 in combination with vinorelbine",{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":223,"PHASE4":225,"NA":227},{"trials":208,"activeCount":8},[],{"trials":210,"activeCount":8},[],{"trials":212,"activeCount":8},[213],{"nctId":214,"briefTitle":215,"status":216,"phases":217,"primaryCompletion":218,"completion":218,"start":219,"enrollment":23,"conditions":220,"interventions":222},"NCT01531764","BIBW 2992 (Afatinib) and Vinorelbine","TERMINATED",[36],"2013-09","2012-07",[221],"Carcinoma Breast Stage IV",[205],{"trials":224,"activeCount":8},[],{"trials":226,"activeCount":8},[],{"trials":228,"activeCount":8},[],{"intervention":230,"totalTrials":9,"cells":231},"MAA for diagnostic SPECT imaging",{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":251,"PHASE4":253,"NA":255},{"trials":233,"activeCount":8},[],{"trials":235,"activeCount":8},[],{"trials":237,"activeCount":8},[238],{"nctId":239,"briefTitle":240,"status":57,"phases":241,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":249},"NCT01186263","Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy",[36],"2011-07","2013-08","2010-07",24,[247,248],"Colorectal Cancer","Liver Metastases",[230,250],"Diagnostic B20- SPECT imaging.",{"trials":252,"activeCount":8},[],{"trials":254,"activeCount":8},[],{"trials":256,"activeCount":8},[],{"intervention":250,"totalTrials":9,"cells":258},{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":269,"PHASE4":271,"NA":273},{"trials":260,"activeCount":8},[],{"trials":262,"activeCount":8},[],{"trials":264,"activeCount":8},[265],{"nctId":239,"briefTitle":240,"status":57,"phases":266,"primaryCompletion":242,"completion":243,"start":244,"enrollment":245,"conditions":267,"interventions":268},[36],[247,248],[230,250],{"trials":270,"activeCount":8},[],{"trials":272,"activeCount":8},[],{"trials":274,"activeCount":8},[],{"intervention":143,"totalTrials":9,"cells":276},{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":287,"PHASE4":289,"NA":291},{"trials":278,"activeCount":8},[],{"trials":280,"activeCount":8},[],{"trials":282,"activeCount":8},[283],{"nctId":135,"briefTitle":136,"status":103,"phases":284,"completion":138,"start":139,"enrollment":127,"conditions":285,"interventions":286},[36],[141],[143,113],{"trials":288,"activeCount":8},[],{"trials":290,"activeCount":8},[],{"trials":292,"activeCount":8},[],{"intervention":294,"totalTrials":9,"cells":295},"Pentoxifylline",{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":315,"PHASE4":317,"NA":319},{"trials":297,"activeCount":8},[],{"trials":299,"activeCount":8},[],{"trials":301,"activeCount":8},[302],{"nctId":303,"briefTitle":304,"status":57,"phases":305,"primaryCompletion":306,"start":307,"enrollment":308,"conditions":309,"interventions":312},"NCT01149304","Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity",[36],"2017-11-15","2009-06",22,[247,248,310,311],"Irradiation Damage","Radiation Induced Liver Disease",[294,313,314],"Ursodeoxycholic Acid","Enoxaparin",{"trials":316,"activeCount":8},[],{"trials":318,"activeCount":8},[],{"trials":320,"activeCount":8},[],{"intervention":313,"totalTrials":9,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":333,"PHASE4":335,"NA":337},{"trials":324,"activeCount":8},[],{"trials":326,"activeCount":8},[],{"trials":328,"activeCount":8},[329],{"nctId":303,"briefTitle":304,"status":57,"phases":330,"primaryCompletion":306,"start":307,"enrollment":308,"conditions":331,"interventions":332},[36],[247,248,310,311],[294,313,314],{"trials":334,"activeCount":8},[],{"trials":336,"activeCount":8},[],{"trials":338,"activeCount":8},[],{"intervention":314,"totalTrials":9,"cells":340},{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":351,"PHASE4":353,"NA":355},{"trials":342,"activeCount":8},[],{"trials":344,"activeCount":8},[],{"trials":346,"activeCount":8},[347],{"nctId":303,"briefTitle":304,"status":57,"phases":348,"primaryCompletion":306,"start":307,"enrollment":308,"conditions":349,"interventions":350},[36],[247,248,310,311],[294,313,314],{"trials":352,"activeCount":8},[],{"trials":354,"activeCount":8},[],{"trials":356,"activeCount":8},[],{"intervention":358,"totalTrials":9,"cells":359},"Saline Irrigation with Ethanol",{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":366,"PHASE4":368,"NA":370},{"trials":361,"activeCount":8},[],{"trials":363,"activeCount":8},[],{"trials":365,"activeCount":8},[],{"trials":367,"activeCount":8},[],{"trials":369,"activeCount":8},[],{"trials":371,"activeCount":8},[372],{"nctId":373,"briefTitle":374,"status":57,"phases":375,"primaryCompletion":376,"completion":376,"start":377,"enrollment":62,"conditions":378,"interventions":380},"NCT02429219","Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate",[39],"2015-02","2013-11",[379],"Benign Prostatic Hypertrophy",[358]]